论文部分内容阅读
HER-2/neu癌基因是erbB-类癌基因族的成员,与表皮生长因子受体有关,但又有区别。已证实这种基因在人乳腺癌细胞系中扩增。本文作者曾研究了189名原发乳腺癌的基因变化,发现 HER-2/neu在30％肿瘤中从2倍扩增到20倍以上。并评价了基因扩增与某些疾病参数的相关性。HER-2/neu是乳腺癌病人总存活率和复发时间的预测因子。在对其他已知的预后因素进行判断时,HER-2/neu仍具有意义。而且,HER-2/neu扩增较新近应用的预后因素(包括激素受体成分)在阳性淋巴结病例中具有大的预后价值。有关资料指出,基因可能在人乳腺癌的生物行为和(或)发病机制中起作用。最近,对化学物质诱导大白鼠神经胶质母细胞瘤DNA的转染研究结果,确定了一种新的转化基因。
The HER-2/neu oncogene is a member of the erbB- oncogene family and is involved in epidermal growth factor receptors, but there are differences. It has been demonstrated that this gene is amplified in human breast cancer cell lines. The authors studied the genetic changes in 189 primary breast cancers and found that HER-2/neu increased from 2 fold to more than 20 fold in 30% of tumors. The relevance of gene amplification to certain disease parameters was evaluated. HER-2/neu is a predictor of overall survival and time to recurrence in breast cancer patients. HER-2/neu still has significance when judging other known prognostic factors. Moreover, the prognostic factors (including hormone receptor components) of HER-2/neu amplification are more prognostic than positive ones in the cases of positive lymph nodes. Relevant data indicate that genes may play a role in the biological behavior and/or pathogenesis of human breast cancer. Recently, a new transforming gene was identified by the results of transfection of chemical substances to induce DNA of rat glioblastoma.